Due to this direct interaction, Keap1 has been identified as a master inhibitor of Nrf2, with its high- or low-expression levels in the human lung, breast, liver, and other somatic cancers, hence, causing changes in endogenous Nrf2 abundances [5,6]. The gene discussed is NFE2L2; the disease is cancer.